35 results about "Carboxybenzyl" patented technology

Belonging to the field of chemical analysis and test, the invention relates to a squarylium cyanine chemical sensor used for Fe<3+> detection and a preparation method thereof. The squarylium cyanine chemical sensor has a symmetrically structured 2, 4, 6-trihydroxy-3, 5-di(p-carboxybenzyl)phenyl)squarylium cyanine compound. The preparation method of the squarylium cyanine chemical sensor used for Fe<3+> detection consists of: preparation of an intermediate 1, 3, 5- trihydroxy-2, 4-di(p-carboxybenzyl)phenyl; and preparation of bis(2, 4, 6-trihydroxy-3, 5-di(p-carboxybenzyl)phenyl)squarylium cyanine. The squarylium cyanine compound provided in the invention has a simple synthesis method and easily controllable reaction conditions, and by means of a simple treatment, a pure product can be obtained. The obtained squarylium cyanine compound has excellent optical performance and optical stability. The squarylium cyanine compound provided in the invention contains carboxyl and hydroxyl groups, has certain water-solubility, and has good selectivity for iron ions.

The present invention relates to an improved process for the preparation of a compound of formula (I), wherein PG1 may be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), benzylidene, methanesulfonyl (Mesyl), toluene sulfonyl (Tosyl) or acyl; its isolation as solid and use for the preparation of the compound of formula (IV), in particular the compound of formula (IV) i.e. [(1R)-3-methyl-1[[(2S)-1-oxo-3-phenyl-2- [(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid with more than 99.95% chiral purity, as measured by HPLC.

The invention discloses a mixed valence europium co-doped strontium magnesium lanthanum oxyapatite silicate luminescent material. The strontium magnesium lanthanum silicate is used as a phosphor matrix and europium ions are used as doping ions. The raw material is Strontium carbonate, magnesium carbonate, lanthanum oxide, silicic acid and europium oxide, while also adding flux boric acid and accelerator, the addition of boric acid is 2%-2.5% of the total mass of raw materials, and the addition of accelerator is 1.5% of the total mass, the luminescent material was prepared by a high-temperature solid-phase method, wherein the accelerator selected bis(triethanolamine) diisopropyl titanate, 2,5-difluorobenzyl zinc bromide, (3,4 ‑Epoxycyclohexyl)ethyltriethoxysilane, (4‑carboxybenzyl)methyldibenzyldicarbamate, bis(2,2,6,6,‑tetramethyl‑3,5 ‑Heptanedionate) calcium and tetrakis (ethylmethylamino) zirconium; the final luminescent material emits pure white light, the color rendering index can reach 90, and the color temperature is around 4000K, which can be used for indoor lighting.

The Pd / Ln heterometallic organic framework and its preparation method and application relate to a chemical functional material and its preparation method and application. In the present invention, the Pd / Ln heterometallic organic framework is represented by Sm(NO 3 ) 3 ·6H 2 O or Eu(NO 3 ) 3 ·6H 2 O or Tb(NO 3 ) 3 ·6H 2 O or Dy(NO 3 ) 3 ·6H 2 O, Potassium tetrachloropalladate K 2 PdCl 4 , Azacyclic carboxylic acid 1,1'-bis(p-carboxybenzyl)-2,2'-bis-imidazole ligand is used as the reaction precursor, and is synthesized by solvothermal method. The molecular formula of the compound is [H 3 O]n[LnPd 2 [L] 2 Cl 4 ]n, where Ln represents Sm or Eu or Tb or Dy; L is 1,1'-bis(p-carboxybenzyl)-2,2'-biimidazole. The catalyst is novel in structure, simple in synthesis, high in yield and stable in air and water. The yield is greater than 99%. The catalyst can be reused by centrifugal separation in ethanol and water-ethanol solvent; it can be separated and recycled by adjusting the pH value in aqueous solution.

The invention discloses a preparation method of a linezolid injection degradation impurity. The method consists of: carrying out condensation reaction on N-carboxybenzyl-3-fluoro-4-morpholinoaniline and R-epichlorohydrin, then conducting acetylation, and finally carrying out hydrolysis aminolysis so as to obtain the linezolid injection degradation impurity N-[(2S)-3-amino-2-hydroxpropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-acetamide, the chemical structure of which is shown as the specification.

The invention provides a novel synthesis method of hepatitis drug velpatasvir.Two intermediate compounds including a compound 4 and a compound III are utilized to synthesize the velpatasvir, the structures of the two compounds are as shown in the following formulas, wherein PG radical is t-butyloxycarboryl (Boc), carboxybenzyl (Cbz), acetyl, benzoyl or (S)-2-methoxyl acyl carbonyl amino-3-methyl-butyryl group (Moc-L-Valyl).

The invention discloses use of a proline derivative in preparation of beta-lactamase inhibitors, and the proline derivative is represented by formula (I), wherein the amide bond in the formula (I) comprises a naturally occurring cis or trans rotamer; R1 is OH or NH2; R2 is o-sulfophenyl, o-sulphonylaminophenyl, m-sulfophenyl, m-sulfonamidophenyl, p-sulfophenyl, p-sulfonamidophenyl, or o-carboxybenzyl. Activity tests show that the proline derivative represented by the formula (I) has a good inhibitory effect on beta-lactamase, especially on NDM-1. By inhibiting of the activity of the beta-lactamase, especially the NDM-1, hydrolysis of beta-lactam antibiotics by the NDM-1 can be reduced or even eliminated, drug resistance caused by the NDM-1 can be alleviated, the curative effect of the antibiotics on bacteria can be restored, and drug-resistant bacterial infections caused by the NDM-1 can be treated.

Disclosed is process for the preparation of a key Rilpivirine intermediate namely, (E)-4-(2-cyanoethenyl)-2,6-dimethylphenylamine hydrochloride (II) by a process comprising reaction of the tetrafluoroborate salt of the diazonium ion of 2,6-dimethyl-4-amino-1-carboxybenzyl phenylamine (VI) with acrylonitrile in presence of palladium acetate, followed by treatment with an acid and its subsequent conversion to the hydrochloride salt (II), wherein the undesired Z isomer is less than 0.5% and provides Rilpivirine hydrochloride having Z isomer less than 0.1%.